TickerFacts.

X4 Pharmaceuticals, Inc (XFOR): Long-Term Debt

Annual figures by period end, from SEC filings.

$75.00M
As of 2025-12-31
$75.00M
As of 2026-06-30
+32.1%
3-year compound annual growth
+18.2%
5-year compound annual growth
2018-12-31: $10.00M2019-12-31: $20.00M2020-12-31: $32.50M2021-12-31: $32.50M2022-12-31: $32.50M2023-12-31: $55.00M2024-12-31: $75.00M2025-12-31: $75.00M$75.00M
2018-12-31 Long-Term Debt (USD) 2025-12-31
Period endedLong-Term DebtChange YoYSource filing
2025-12-31$75.00M0.0%2026-03-17, Balance as of period end
2024-12-31$75.00M+36.4%2026-03-17, Balance as of period end
2023-12-31$55.00M+69.2%2025-03-26, Balance as of period end
2022-12-31$32.50M0.0%2024-03-21, Balance as of period end
2021-12-31$32.50M0.0%2023-03-21, Balance as of period end
2020-12-31$32.50M+62.5%2022-03-17, Balance as of period end
2019-12-31$20.00M+100.0%2021-03-19, Balance as of period end
2018-12-31$10.00Mn/a2020-03-12, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
X4 Pharmaceuticals, Inc (XFOR)2025-12-31$75.00M0.0%
Editas Medicine, Inc. (EDIT)2024-12-31$57.43Mn/a
Fennec Pharmaceuticals Inc. (FENC)2024-12-31$19.34M-37.5%
Alector, Inc. (ALEC)2025-12-31$10.00M0.0%
Agenus Inc (AGEN)2025-12-31$44.66M+34.6%
TScan Therapeutics, Inc. (TCRX)2025-12-31$32.53M+1.4%
Adaptimmune Therapeutics PLC (ADAPY)2024-12-31$54.28Mn/a
Tarsus Pharmaceuticals, Inc. (TARS)2025-12-31$72.44M+0.8%
ADMA Biologics, Inc. (ADMA)2025-12-31$72.14M-0.3%

Compare XFOR, EDIT, FENC, ALEC side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗